Hey all, welcome back to the real-life pharmacology podcast. I'm your host, Eric Christensen.

If you want to track us down, check us out at real-life pharmacology.com. Definitely take

advantage of that free 30-plus page PDF on the top 200 drugs if you're studying for

pharmacology or just looking to pick up some

clinical practice pearls. Definitely go snag that PDF for free at real art pharmacology.com

and we'll also get you updates as far as when we have new podcasts available.

So the drug I'm going to cover today is a combination product that I am seeing periodically now.

Fluticazone, umacladinium, and volantorol is the combination.

So this is an inhaled medication primarily for the use of COPD.

It's a combination medication, obviously. It's got three different drugs.

So the Fluticazone is an inhaled corticosteroid.

Umaclidinium is a long-acting anticholinergic and volantorol is a long-acting

beta-2 agonist. So one of the big clinical advantages with this medication is its dose once a day

and we've got three medications within it.

Now that can be a good and a bad thing.

Obviously the once daily is a huge advantage for patients.

It's a very convenient thing to use.

You can factor it into your daily routine versus a medication

that, you know, you maybe do two or three times a day. That gets a little bit trickier sometimes

for some patients to follow that regimen. So more doses you add throughout the day, the more and

more likely that you're going to see patients skip doses, missed doses,

forget doses, or whatever the case may be there.

...